Market Access For Biopharmaceuticals: New Challenges
Author:
Affiliation:
1. School of Public Health and Business School, Columbia University, in New York City
Publisher
Health Affairs (Project Hope)
Subject
Health Policy
Reference18 articles.
1. E. Licking et al. “Reviewing 2005 and Previewing 2006: The Top Stories,”In Vivo(January 2006 ): 45 –52
2. Tufts Center for the Study of Drug Development,Outlook 2001(Boston: Tufts University, 2001), as reported in J.D. Kleinke , “The Price of Progress: Prescription Drugs in the Health Care Market,”Health Affairs20, no. 5 ( 2001 ): 43 –60
3. . See also F.R. Lichtenberg , “Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 MEPS,”Health Affairs20, no. 5 ( 2001 ): 241 –251.
4. Access Versus Excess: Value-Based Cost Sharing For Prescription Drugs
5. Biotechnology and Managed Care
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A systematic review of moral reasons on orphan drug reimbursement;Orphanet Journal of Rare Diseases;2021-06-30
2. Analytical and Sales Data Comparison of Reference Product of Insulin Aspart and its Biosimilar in Turkey;Marmara Pharmaceutical Journal;2017-06-24
3. Identifying stakeholder opinion regarding access to “high-cost medicines”: A systematic review of the literature;Open Medicine;2014-06-01
4. The cost-effectiveness of biopharmaceuticals;mAbs;2012-03
5. Availability, Health-Care Costs, and Utilization Patterns of Biologics in Taiwan;Value in Health;2012-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3